Miravant to confirm value of AMD (age-related macular degeneration) therapy for FDA
This article was originally published in Clinica
Executive Summary
At the request of the US FDA, Miravant Medical Technologies is to conduct a confirmatory clinical trial of its photodynamic therapy (PDT) for wet age-related macular degeneration (AMD).